

## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

### **SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Ivermectin / Abamectin Liquid Formulation

Manufacturer or supplier's details

Company name of supplier : MSD

Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

**GHS Classification** 

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Skin corrosion/irritation : Category 2

Serious eye damage/eye

irritation

Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity

- single exposure (Oral)

Category 1 (Central nervous system)

Specific target organ toxicity

- single exposure

Category 3

Specific target organ toxicity

- repeated exposure (Oral)

: Category 1 (Central nervous system)

Specific target organ toxicity

- repeated exposure

Category 2 (Central nervous system)

**GHS** label elements

Hazard pictograms

**(!)** 

Signal Word : Danger

Hazard Statements : H302 + H332 Harmful if swallowed or if inhaled.

H315 Causes skin irritation.



## **Ivermectin / Abamectin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 7.1 30.09.2023 1210013-00023 Date of first issue: 10.01.2017

H319 Causes serious eye irritation.

H335 May cause respiratory irritation.

H360Df May damage the unborn child. Suspected of damaging

fertility.

H370 Causes damage to organs (Central nervous system) if

swallowed.

H372 Causes damage to organs (Central nervous system)

through prolonged or repeated exposure if swallowed.

H373 May cause damage to organs (Central nervous system)

through prolonged or repeated exposure.

#### **Precautionary Statements**

#### Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe mist or vapors.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

#### Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON

CENTER or doctor/ physician if you feel unwell. Rinse mouth.

P302 + P352 IF ON SKIN: Wash with plenty of water.

P304 + P340 + P312 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/ physician if you feel unwell.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P308 + P311 IF exposed or concerned: Call a POISON

CENTER/ doctor.

P332 + P313 If skin irritation occurs: Get medical advice/ atten-

P337 + P313 If eye irritation persists: Get medical advice/ atten-

P362 + P364 Take off contaminated clothing and wash it before reuse.

#### Storage:

P405 Store locked up.

#### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards

None known.

### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture



## **Ivermectin / Abamectin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 7.1 30.09.2023 1210013-00023 Date of first issue: 10.01.2017

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
N-Methyl-2-pyrrolidone	872-50-4	>= 20 -< 30
Ivermectin	70288-86-7	>= 1 -< 5
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	>= 1 -< 5
(dl)-a-Tocopheryl acetate	7695-91-2	< 0.1

#### **SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms

and effects, both acute and

delayed

Harmful if swallowed or if inhaled. Causes skin irritation.

Causes serious eye irritation. May cause respiratory irritation.

May damage the unborn child. Suspected of damaging fertili-

ty.

Causes damage to organs if swallowed.

Causes damage to organs through prolonged or repeated

exposure if swallowed.

May cause damage to organs through prolonged or repeated

exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

Dry chemical

Unsuitable extinguishing

media

: None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapors.

Do not swallow.



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease,

should consult their physician regarding working with

respiratory irritants or sensitizers.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Keep in a cool, well-ventilated place.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Ivermectin	70288-86-7	TWA	30 μg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	300 μg/100 cm2	Internal	
abamectin (combination of avermectin B1a and avermec- tin B1b) (ISO)	71751-41-2	TWA	15 μg/m3 (OEB 3)	Internal	
		Wipe limit	150 µg/100 cm <sup>2</sup>	Internal	
(dl)-a-Tocopheryl acetate	7695-91-2	TWA	5000 ug/m3 (OEB 1)	Internal	



## **Ivermectin / Abamectin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 7.1 30.09.2023 1210013-00023 Date of first issue: 10.01.2017

### **Biological occupational exposure limits**

Components	CAS-No.	Control parameters	Biological specimen	Sam- pling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy- N-methyl-2- pyrrolidone	Urine	End of shift	100 mg/l	MX BEI
		5-Hydroxy- N-methyl-2- pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

**Engineering measures** : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Combined particulates and organic vapor type

Filter type

Material

Hand protection

: Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : liquid

Color : light yellow



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

Odor : characteristic

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point :  $> 100 \, ^{\circ}\text{C}$ 

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 0.91 - 1.00 mg/l

Solubility(ies)

Water solubility : insoluble

Partition coefficient: n-

octanol/water

: Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

## **SECTION 11. TOXICOLOGICAL INFORMATION**

### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

#### **Acute toxicity**

Harmful if swallowed or if inhaled.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: 981.33 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1.84 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Components:

N-Methyl-2-pyrrolidone:

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

LD50 (Monkey): > 24 mg/kg

Target Organs: Central nervous system Symptoms: Vomiting, Dilatation of the pupil Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

LDLo (Monkey): 24 mg/kg

Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg

LD50 (Rabbit): 2,000 mg/kg

(dl)-a-Tocopheryl acetate:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 3,000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Causes skin irritation.

**Components:** 

N-Methyl-2-pyrrolidone:

Result : Skin irritation

Ivermectin:

Species : Rabbit

Result : No skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : No skin irritation



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

(dl)-a-Tocopheryl acetate:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

**Components:** 

N-Methyl-2-pyrrolidone:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Ivermectin:

Species : Rabbit

Result : Mild eye irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : Mild eye irritation

(dl)-a-Tocopheryl acetate:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

**Components:** 

N-Methyl-2-pyrrolidone:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact Species : Mouse

Method : OECD Test Guideline 429

Result : negative

Remarks : Based on data from similar materials

Ivermectin:

Routes of exposure : Dermal Species : Humans

Result : Does not cause skin sensitization.



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximization Test Routes of exposure : Skin contact

Result : Not a skin sensitizer.

(dl)-a-Tocopheryl acetate:

Test Type : Draize Test
Routes of exposure : Skin contact
Species : Humans
Result : negative

#### Germ cell mutagenicity

Not classified based on available information.

### **Components:**

### N-Methyl-2-pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion Method: OECD Test Guideline 474

Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Hamster

Application Route: Ingestion Method: OECD Test Guideline 475

Result: negative

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts

Result: negative

Test Type: Mouse Lymphoma



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

Result: negative

## abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: Alkaline elution assay

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

(dl)-a-Tocopheryl acetate:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

### Carcinogenicity

Not classified based on available information.

### **Components:**

## N-Methyl-2-pyrrolidone:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Species : Rat

Application Route : inhalation (vapor)

Exposure time : 2 Years
Result : negative

Ivermectin:

Species : Rat



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

Application Route : Oral

NOAEL : 1.5 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Species : Mouse Application Route : Oral

NOAEL : 2.0 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 93 weeks
Result : negative

### (dl)-a-Tocopheryl acetate:

Species : Rat
Application Route : Ingestion
Exposure time : 104 weeks
Result : negative

#### Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

### **Components:**

### N-Methyl-2-pyrrolidone:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 416

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 414

Result: positive

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: inhalation (vapor)

Result: positive

Test Type: Embryo-fetal development

Species: Rabbit



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

**Application Route: Ingestion** 

Result: positive

Reproductive toxicity - As-

sessment

: Clear evidence of adverse effects on development, based on

animal experiments.

Ivermectin:

Effects on fertility : Test Type: Fertility

Species: Rat

**Application Route: Oral** 

Fertility: NOAEL: 0.6 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development

Species: Mouse

**Application Route: Oral** 

Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 0.4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the

offspring were detected.

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

Test Type: Development

Species: Rabbit

Application Route: Oral

Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: NOAEL: 0.12 mg/kg body

weight

Result: Fetotoxicity.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Mouse

**Application Route: Oral** 



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight Developmental Toxicity: NOAEL: 0.2 mg/kg body weight

Result: Cleft palate

Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 2 mg/kg body weight

Result: Cleft palate, Teratogenic effects., Reduced embryonic

survival

Remarks: Adverse developmental effects were observed

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1.6 mg/kg body weight

Result: Teratogenic effects.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal

experiments.

(dl)-a-Tocopheryl acetate:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening

test

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rabbit

Application Route: Ingestion

Result: negative

STOT-single exposure

May cause respiratory irritation.

Causes damage to organs (Central nervous system) if swallowed.

**Components:** 

N-Methyl-2-pyrrolidone:

Assessment : May cause respiratory irritation.

Ivermectin:

Target Organs : Central nervous system Assessment : Causes damage to organs.



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

### STOT-repeated exposure

Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

### Components:

### Ivermectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Routes of exposure : Ingestion

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

### **Components:**

## N-Methyl-2-pyrrolidone:

Species : Rat, male
NOAEL : 169 mg/kg
LOAEL : 433 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Method : OECD Test Guideline 408

Species : Rat NOAEL : 0.5 mg/l LOAEL : 1 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 96 Days

Method : OECD Test Guideline 413

Species : Rabbit
NOAEL : 826 mg/kg
LOAEL : 1,653 mg/kg
Application Route : Skin contact
Exposure time : 20 Days

#### Ivermectin:

Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Central nervous system

Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

NOAEL : 1.2 mg/kg Application Route : Oral Exposure time : 2 Weeks

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 0.4 mg/kg
LOAEL : 0.8 mg/kg
Application Route : Oral
Exposure time : 3 Months

Target Organs : spleen, Bone marrow, Kidney

### abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

Species : Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Central nervous system

### (dl)-a-Tocopheryl acetate:

Species : Rat
NOAEL : 500 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

### **Aspiration toxicity**

Not classified based on available information.



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

#### Experience with human exposure

**Components:** 

N-Methyl-2-pyrrolidone:

Skin contact : Symptoms: Skin irritation

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom-

iting, anorexia, Lack of coordination

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion : Symptoms: May cause, Tremors, Diarrhea, central nervous

system effects, Salivation, tearing

#### **SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity** 

**Components:** 

N-Methyl-2-pyrrolidone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 1,000 mg/l

Exposure time: 24 h Method: DIN 38412

Toxicity to algae/aquatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l

Exposure time: 72 h

EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l

Exposure time: 72 h

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 12.5 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 600 mg/l

Exposure time: 30 min Method: ISO 8192

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.000025 mg/l

Exposure time: 48 h



## **Ivermectin / Abamectin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 7.1 30.09.2023 1210013-00023 Date of first issue: 10.01.2017

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 μg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l

Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l

Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l

Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 0.022 µg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0.34 μg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l

Exposure time: 32 d

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.03 µg/l

Exposure time: 21 d

NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l

Exposure time: 28 d

Toxicity to microorganisms :

EC50: > 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

(dl)-a-Tocopheryl acetate:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): >=

100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l

Exposure time: 28 d

Toxicity to microorganisms : EC50: > 927 mg/l

Exposure time: 30 min Method: ISO 8192

#### Persistence and degradability

### **Components:**

N-Methyl-2-pyrrolidone:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 73 % Exposure time: 28 d

Method: OECD Test Guideline 301C

Ivermectin:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 240 d

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

(dl)-a-Tocopheryl acetate:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 21.7 - 31 %

Exposure time: 28 d

Method: OECD Test Guideline 301C

**Bioaccumulative potential** 

**Components:** 

N-Methyl-2-pyrrolidone:

Partition coefficient: n- : log Pow: -0.46



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

octanol/water Method: OECD Test Guideline 107

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-

octanol/water

log Pow: 3.22

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-

octanol/water

log Pow: 4

Mobility in soil

**Components:** 

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environ-

mental compartments

: log Koc: > 3.6

Other adverse effects

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS** 

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION** 

International Regulations

**UNRTDG** 

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

**IATA-DGR** 

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), Ivermectin)

Class : 9



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 964

aircraft)

Packing instruction (passen: 964

ger aircraft)

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### **Domestic regulation**

NOM-002-SCT

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### **SECTION 15. REGULATORY INFORMATION**

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, essential chemical products and machinery for

producing capsules, tablets and pills.

Not applicable

## The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined



## **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

#### **SECTION 16. OTHER INFORMATION**

Revision Date : 30.09.2023 Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)

MX BEI : Official Mexican Norm NOM-047-SSA1-2011, Environmental

Health - Biological exposure indices for workers occupational-

ly exposed to chemical agents

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature: SDS - Safety Data Sheet: TCSI - Taiwan Chemical Substance Inventory: TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Data Sheet cy, http://echa.europa.eu/

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.



# **Ivermectin / Abamectin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 7.1
 30.09.2023
 1210013-00023
 Date of first issue: 10.01.2017

MX/Z8